Based on the Aptose Biosciences Inc stock forecast from 1 analysts, the average analyst target price for Aptose Biosciences Inc is CAD 1.00 over the next 12 months. Aptose Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aptose Biosciences Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Aptose Biosciences Inc’s stock price was CAD 0.27. Aptose Biosciences Inc’s stock price has changed by +8.00% over the past week, -19.40% over the past month and -90.25% over the last year.
No recent analyst target price found for Aptose Biosciences Inc
No recent average analyst rating found for Aptose Biosciences Inc
Company Overview Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Read Less
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily...Read More
Frequently Asked Questions About Aptose Biosciences Inc (APS:CA) Stock
Based on ratings from 1 analysts Aptose Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on APS:CA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for APS:CA is CAD 1.00 over the next 12 months. The maximum analyst target price is CAD 1 while the minimum anlayst target price is CAD 1.
Unfortunately we do not have enough data on APS:CA's stock to indicate if its overvalued.
The last closing price of APS:CA's stock was CAD 0.27.
The most recent market capitalization for APS:CA is CAD 0.02B.
Based on targets from 1 analysts, the average taret price for APS:CA is projected at CAD 1.00 over the next 12 months.
This means that APS:CA's stock price may go up by +270.37% over the next 12 months.
We can't find any ETFs which contains Aptose Biosciences Inc's stock.
As per our most recent records Aptose Biosciences Inc has 35 Employees.
Aptose Biosciences Inc's registered address is 251 Consumers Road, Toronto, ON, Canada, M2J 4R3.
You can get more information about it from Aptose Biosciences Inc's website at https://www.aptose.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Aptose Biosciences Inc (APS:CA) Stock
Based on ratings from 1 analysts Aptose Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on APS:CA's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for APS:CA is CAD 1.00 over the next 12 months. The maximum analyst target price is CAD 1 while the minimum anlayst target price is CAD 1.
Unfortunately we do not have enough data on APS:CA's stock to indicate if its overvalued.
The last closing price of APS:CA's stock was CAD 0.27.
The most recent market capitalization for APS:CA is CAD 0.02B.
Based on targets from 1 analysts, the average taret price for APS:CA is projected at CAD 1.00 over the next 12 months.
This means that APS:CA's stock price may go up by +270.37% over the next 12 months.
We can't find any ETFs which contains Aptose Biosciences Inc's stock.
As per our most recent records Aptose Biosciences Inc has 35 Employees.
Aptose Biosciences Inc's registered address is 251 Consumers Road, Toronto, ON, Canada, M2J 4R3.
You can get more information about it from Aptose Biosciences Inc's website at https://www.aptose.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APS:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
